Return to Thyroid Cancer Specialty Channel

Thyroid Cancer Interactive Features

True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
Stay in the know.
OncNet Newsletter